Acute systemic inflammation enhances endothelium-dependent tissue plasminogen activator release in men

Journal of the American College of Cardiology

Volumn 41, Issue 2, 2003, Pages 333-339

  Chia, Stanley ^a,b   Ludlam, Christopher A ^b   Fox, Keith A A ^a   Newby, David E ^a  

^a UNIVERSITY OF EDINBURGH   (United Kingdom)

^b ROYAL INFIRMARY OF EDINBURGH   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLCHOLINE; BRADYKININ; INTERLEUKIN 6; NITROPRUSSIDE SODIUM; SALMONELLOSIS VACCINE; TISSUE PLASMINOGEN ACTIVATOR;

ADULT; ARTICLE; ATHEROSCLEROSIS; CARDIOVASCULAR RISK; CONTROLLED STUDY; CYTOKINE RELEASE; FIBRINOLYSIS; HEART PROTECTION; HUMAN; HUMAN EXPERIMENT; INFLAMMATION; LEUKOCYTE COUNT; MALE; NORMAL HUMAN; PRIORITY JOURNAL; VACCINATION;

ACETYLCHOLINE; ADULT; BRACHIAL ARTERY; BRADYKININ; CORONARY ARTERIOSCLEROSIS; CROSS-OVER STUDIES; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; ENDOTHELIUM, VASCULAR; HUMANS; INFLAMMATION; MALE; NITROPRUSSIDE; PLASMINOGEN ACTIVATOR INHIBITOR 1; REGIONAL BLOOD FLOW; TISSUE PLASMINOGEN ACTIVATOR; TYPHOID-PARATYPHOID VACCINES;

EID: 0037438527     PISSN: 07351097     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0735-1097(02)02701-8     Document Type: Article

References (40)

1. Ross R. Atherosclerosis - an inflammatory disease. N Engl J Med 1999;340:115-25.
2. Roivainen M, Viik-Kajander M, Palosuo T, et al. Infections, inflammation, and the risk of coronary heart disease. Circulation 2000;101:252-7.
3. Valtonen V, Kuikka A, Syrjanen J. Thrombo-embolic complications in bacteraemic infections. Eur Heart J 1993;14 Suppl K:20-3.
4. Meier CR, Jick SS, Derby LE, Vasilakis C, Jick H. Acute respiratory-tract infections and risk of first-time acute myocardial infarction. Lancet 1998;351:1467-71.
5. Quartin AA, Schein RMH, Kett DH, Peduzzi PN. Magnitude and duration of the effect of sepsis on survival. JAMA 1997;277:1058-63.
6. Mamode N, Cobbe S, Pollock JG. Infarcts after surgery. Br Med J 1995;310:1215-6.
7. Liuzzo G, Biasucci L, Gallimore JR, et al. The prognostic value of C-reactive protein and serum amyloid A protein in severe unstable angina. N Engl J Med 1994;331:417-24.
8. Ridker PM, Rifai N, Pfeffer M, Sacks F, Lepage S, Braunwald E. Elevation of tumor necrosis factor-alpha and increased risk of recurrent coronary events after myocardial infarction. Circulation 2000;101:2149-53.
9. Biasucci LM, Vitelli A, Liuzzo G, et al. Elevated levels of interleukin-6 in unstable angina. Circulation 1996;94:874-7.
10. Biasucci LM, Liuzzo G, Fantuzzi G, et al. Increasing levels of interleukin (IL)-1Ra and IL-6 during the first 2 days of hospitalization in unstable angina are associated with increased risk of in-hospital coronary events. Circulation 1999;99:2079-84.
11. Ridker PM, Cushman P, Stampfer MJ, Tracy RP, Hennekens CH. Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. N Engl J Med 1997;336:973-9.
12. Ridker PM, Hennekens CH, Buring JE, Rifai N. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med 2000;342:836-43.
13. Ridker PM, Rifai N, Stampfer MJ, Hennekens CH. Plasma concentration of interleukin-6 and the risk of future myocardial infarction among apparently healthy men. Circulation 2000;101:1767-72.
14. Vane JR, Anggard EE, Botting RM. Regulatory functions of the vascular endothelium. N Engl J Med 1990;323:27-36.
15. van den Eijnden-Schrauwen Y, Kooistra T, de Vries REM, Emeis JJ. Studies on the acute release of tissue-type plasminogen activator from human endothelial cells in vitro and in rats in vivo: evidence for a dynamic storage pool. Blood 1995;85:3510-7.
16. Fox KAA, Robison AK, Knabb RM, Rosamond TL, Sobel BE, Bergmann SR. Prevention of coronary thrombosis with subthrombolytic doses of tissue-type plasminogen activator. Circulation 1984;72:1346-54.
17. Brommer EJP. The level of extrinsic plasminogen activator (t-PA) during clotting as a determinant of the rate of fibrinolysis: inefficiency of activators added afterwards. Thromb Res 1984;34:109-15.
18. Rosenberg RD, Aird WC. Vascular-bed-specific hemostasis and hypercoagulable states. N Engl J Med 1999;340:1555-64.
19. Newby DE, Wright RA, Ludlam CA, Fox KA, Boon NA, Webb DJ. An in vivo model for the assessment of the acute fibrinolytic capacity of the endothelium. Thromb Haemost 1997;78:1242-8.
20. Newby DE, Wright RA, Dawson P, et al. The L-arginine: nitric oxide pathway contributes to the acute release of tissue plasminogen activator in vivo in man. Cardiovasc Res 1998;38:485-92.
21. Newby DE, Wright RA, Labinjoh C, et al. Endothelial dysfunction, impaired endogenous fibrinolysis, and cigarette smoking: a mechanism for arterial thrombosis and myocardial infarction. Circulation 1999;99:1411-5.
22. Hingorani AD, Cross J, Kharbanda RK, et al. Acute systemic inflammation impairs endothelium-dependent dilatation in humans. Circulation 2000;102:994-9.
23. Brown NJ, Gainer JV, Stein CM, Vaughan DE. Bradykinin stimulates tissue plasminogen activator release in human vasculature. Hypertension 1999;33:1431-5.
24. Panza JA, Quyyumi AA, Brush JE Jr., Epstein SE. Abnormal endothelium-dependent vascular relaxation in patients with essential hypertension. N Engl J Med 1990;323:22-7.
25. Calver A, Collier J, Vallance P. Inhibition and stimulation of nitric oxide synthesis in the forearm arterial bed of patients with insulin-dependent diabetes. J Clin Invest 1992;90:2548-54.
26. Chowienczyk P, Watts G, Cockcroft J, Ritter JM. Impaired endothelium dependent vasodilation of forearm resistance vessels in hypercholesterolaemia. Lancet 1992;340:1430-2.
27. Chowienczyk P, Cockcroft JR, Ritter JM. Blood flow responses to intra-arterial acetylcholine in man: effects of basal flow and conduit vessel length. Clin Sci 1994;87:45-51.
28. Emeis JJ, van den Eijnden-Schrauwen Y, van den Hoogen CM, de Priester W, Westmuckett A, Lupu F. An endothelial storage granule for tissue-type plasminogen activator. J Cell Biol 1997;139:245-56.
29. Brown NJ, Nadeau JH, Vaughan DE. Selective stimulation of tissue plasminogen activator (t-PA) in vivo by infusion of bradykinin. Thromb Haemost 1997;77:522-5.
30. Labinjoh C, Newby DE, Pellegrini MP, Johnston NR, Boon NA, Webb DJ. Potentiation of bradykinin-induced tissue plasminogen activator release by angiotensin-converting enzyme inhibition. J Am Coll Cardiol 2001;38:1402-8.
31. Labinjoh C, Newby DE, Dawson P, et al. Fibrinolytic actions of intra-arterial angiotensin II and bradykinin in vivo in man. Cardiovasc Res 2000;47:707-14.
32. Rojkjaer R, Schmaier AH. Activation of the plasma kallikrein/kinin system on endothelial cells. Proc Assoc Am Phys 1999;111:220-7.
33. Dichek D, Quertermous T. Thrombin regulation of mRNA levels of tissue plasminogen activator and plasminogen activator inhibitor-1 in cultured human umbilical vein endothelial cells. Blood 1989;74:222-8.
34. Levin EG, Santell L. Stimulation and desensitization of tissue plasminogen activator release from human endothelial cells. J Biol Chem 1988;263:9360-5.
35. van der Poll T, Coyle SM, Levi M, et al. Effect of a recombinant dimeric tumor necrosis factor receptor on inflammatory responses to intravenous endotoxin in normal humans. Blood 1997;89:3727-34.
36. Kharbanda RK, Walton B, Allen M, et al. Prevention of inflammation-induced endothelial dysfunction: a novel vasculo-protective action of aspirin. Circulation 2002;105:2600-4.
37. Hamsten A, Wiman B, de Faire U, Blomback M. Increased plasma levels of a rapid inhibitor of tissue plasminogen activator in young survivors of myocardial infarction. N Engl J Med 1985;313:1557-63.
38. Newby DE, Sciberras DG, Mendel CM, Gertz BJ, Boon NA, Webb DJ. Intra-arterial substance P mediated vasodilatation in the human forearm: pharmacology, reproducibility and tolerability. Br J Clin Pharmacol 1997;43:493-9.
39. Newby DE, Witherow FN, Wright RA, et al. Hypercholesterolemia and lipid lowering therapy do not affect the acute endogenous fibrinolytic capacity in vivo. Heart 2002;87:48-53.
40. Newby DE, MacLeod AL, Uren NG, et al. Impaired coronary tissue plasminogen activator release is associated with coronary atherosclerosis and cigarette smoking: direct link between endothelial dysfunction and atherothrombosis. Circulation 2001;103:1936-41.